Innate Pharma Seeks to Raise EUR23 Million from Share Offering

01:06 AM EDT, 08/14/2026 (MT Newswires) -- Innate Pharma (IPH.PA) plans to raise 22.5 million euros from an offering of its shares, according to a Thursday filing. European and US institutional healthcare specialist investors are anchoring the offering, among other investors. The final terms will be disclosed upon completion of an accelerated bookbuilding process that launched immediately after the announcement. The clinical-stage biotechnology company earmarked net proceeds for the clinical development of IPH4502, advancing its preclinical portfolio of antibody-drug conjugates, and for working capital and general corporate expenditures.